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What is already known about this subject? 
• Previous GWAS identified loci in inflammatory genes (CNTN-5, ZNF724 and 
MIR302F) as risk factors for transition from asymptomatic hyperuricaemia (AH) to gout, 
and was conducted in Japanese population. 
What does this study add? 
• This is the largest GWAS of gout cases and AH controls, and the first in Caucasian 
population. 
• 13 variants in urate transporters and metabolic genes, but none in inflammatory genes 
associated with transition from AH to gout. A novel GWAS-significant gout risk locus 
was identified in ADH1B gene. 
• Genetic and demographic factors performed moderately well in predicting gout status 
in AH.  
How might this impact on clinical practice? 
• Adults with AH should be advised lifestyle and dietary interventions that lower their 
serum urate levels in order to reduce their risk of gout.  
  
ABSTRACT 
Objectives: To perform a genome-wide association study (GWAS) of gout cases vs. 
asymptomatic hyperuricaemia (AH) controls, and gout cases vs. normouricaemia controls, 
and to generate a polygenic risk score (PRS) to determine gout-case vs. AH-control status. 
Methods: Gout cases and AH controls (serum urate (SU) ≥6mg/dL) from the UK Biobank 
were divided into discovery (4,934 cases, 56,948 controls) and replication (2,115 cases, 
24,406 controls) cohorts. GWAS was conducted and PRS generated using summary statistics 
in discovery cohort as the base dataset and the replication cohort as the target dataset. The 
predictive ability of the model was evaluated. GWAS were performed to identify variants 
associated with gout compared to normouricaemic controls using SU <6.0 mg/dL and <7.0 
mg/dL thresholds respectively. 
Results: Thirteen independent SNPs in ABCG2, SLC2A9, SLC22A11, GCKR, MEPE, 
PPM1K-DT, LOC105377323, and ADH1B reached genome-wide significance and replicated 
as predictors of AH to gout transition. Twelve of 13 associations were novel for this transition, 
and rs1229984 (ADH1B) was identified as GWAS locus for gout for the first time. The best 
PRS model was generated from association data of 17 SNPs; and had predictive ability of 
58.5% that increased to 69.2% upon including demographic factors. Two novel SNPs 
rs760077(MTX1) and rs3800307(PRSS16) achieved GWAS significance for association with 
gout compared with normouricaemic controls using both SU thresholds.  
Conclusion: The association of urate transporters with gout supports the central role of 
hyperuricaemia in its pathogenesis. Larger GWAS are required to identify if variants in 
inflammatory pathways contribute to progression from AH to gout. 
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INTRODUCTION Gout is a common form of inflammatory arthritis caused by the deposition 
of monosodium urate (MSU) crystals. Elevated serum urate (SU) concentration is the 
precursor to MSU crystal deposition, and the onset of gout.1 However, the majority of people 
with hyperuricemia do not develop gout. For instance, in the USA, the prevalence of 
hyperuricaemia (defined as SU >7.0 mg/dL) is 20%, while that of gout is 3.9%.2 The reason(s) 
why only some people with hyperuricaemia develop gout is poorly understood. Genome wide 
association studies (GWAS) have improved the understanding of the pathophysiology of 
hyperuricaemia and gout over the last 10-15 years. For instance, genetic variants located in 
urate transporters such as the ABCG2, SLC2A9, and SLC22A11 genes have been identified 
as risk loci for both hyperuricemia and gout.3-6 Additional genetic variants such as GCKR and 
ALDH2 that play important roles in carbohydrate and alcohol metabolism respectively have 
been associated with both phenotypes.5 7-9 However, the genetic variants associated with 
progression from hyperuricaemia to gout remain poorly understood. To date, only a single 
relatively small GWAS (n=6,009 Japanese adults, 2,860 with gout) has examined this and 
revealed two novel loci: CNTN5 and MIR302F, that participate in immune and inflammatory 
responses.10 However, the identified polymorphism in CNTN5 is intronic while the SNP near 
MIR302F is intergenic. Further analyses in independent populations and larger sample sizes 
are needed to improve the understanding of the molecular mechanisms involved in 
transitioning from asymptomatic hyperuricaemia (AH) to gout.  
Thus, the purpose of this study was to examine the genetic variants associated with transition 
from hyperuricaemia to gout. In order to meet this objective, we performed a GWAS using 
gout cases and [1] AH controls (SU ≥6.0 mg/dL), [2] normouricaemia controls with SU <6.0 
mg/dL, and [3] normouricaemia controls with SU <7.0 mg/dL derived from the UK Biobank 
resource. Genotype data was used to develop a polygenic risk score (PRS) to predict gout-
case and AH-control status. We chose a threshold of ≥6.0 mg/dL to define AH as the risk of 
incident gout increases above this SU level.11  
  
METHODS  
Data source: This study was conducted using data from the UK Biobank resource (Project ID 
45987). Briefly, the UK Biobank is a prospective study of ~500,000 participants, aged 40-60 
years and recruited across England, Wales and Scotland between the years 2006 and 2010. 
Data were collected on lifestyle and sociodemographic information, cognitive function, health 
status, and family medical history. Participants had standard physical and functional 
measurements, and provided blood samples for genetic analyses. Details about recruitment 
and samples processing for genotyping are described elsewhere.12 13 
Subjects: For this research, three phenotypes were derived from the UK Biobank cohort. 
Gout cases: Gout was defined as present if any of the following criteria were met:14 self-
reported physician diagnosed gout; urate lowering therapy (ULT) prescription without a 
hospital diagnosis of lymphoma or leukaemia (ICD-10 codes C81-C96); or a primary or 
secondary diagnosis of gout in hospital discharge letters using the ICD-10 codes M10, M100-
M14, and M109. Participants with self-reported physician diagnosed gout were excluded if 
their SU was <6.0 mg/dL and they did not report prescription of ULT at the UK Biobank visit.  
AH controls: Participants with SU ≥6.0 mg/dL and not classified as gout. A threshold of ≥6.0 
mg/dl was chosen as it associates with incident gout in prospective studies.11 
Normouricaemia controls: Participants with SU <6.0 mg/dL and not classified as gout14 were 
considered as normouricaemia controls. Given the uncertainty around definition of normal SU, 
for example SU <6.0 mg/dL being the treatment threshold for treat-to-target ULT while 
epidemiological studies use a cut-off of <7.0 mg/dl, another group of normouricaemia controls 
was ascertained with  SU <7.0 mg/dl and not classified as gout14. 
 
Genotyping and quality control: UK Biobank samples were genotyped by Affymetrix using two 
arrays: The UK BiLEVE Axiom array (n=49,950; 807,411 markers), and the UK Biobank Axiom 
array (n=438,427; 825,927 markers). These arrays shared 95% of content, resulting in 
>805,000 genotyped variants for 488,288 participants. For this study, participants with non-
European ancestry were excluded to avoid population stratification. Thus, genotyping data for 
409,629 European descendants were available following UK Biobank centrally performed 
quality control (QC) procedures. Detailed information about genotyping and QC have been 
described previously.13 15 Further stringent QC filters were applied using PLINK 1.9.16 
Individuals with a kinship coefficient equivalent to second degree (or greater) relatives were 
excluded. Individuals were also excluded if they had a heterozygosity ±3 standard deviations 
(SD) from the mean, a call rate <90%, or were identified as gender mismatches. Markers with 
a call rate <95%, or those deviating from Hardy-Weinberg equilibrium (Bonferroni corrected p 
value threshold p=6.82x10-8) were removed from the dataset.  
Gout vs. AH: A sample of 354,825 individuals with 717,091 genotyped SNPs were included in 
this analysis, from which the phenotypes of interest were derived. The cohort comprised of 
7,049 cases and 81,354 controls that were divided into two datasets: 70% (n=61,882) was 
used as the discovery dataset, and the remaining 30% (n=26,521) was used as the replication 
dataset (Figure 1). 
Gout vs. normouricaemia: Two separate GWAS were conducted, using gout cases and 64,424 
controls with SU <6.0 mg/dL, and 79,531 controls with SU <7.0 mg/dL respectively.   
 
Statistical analyses: Baseline data were summarised using mean (SD) for continuous 
variables, and number (%) for categorical variables. Independent sample t-test and chi-square 
test were used to compare continuous and categorical data respectively.  
 
Gout vs. AH GWAS: Discovery and replication association tests were performed using PLINK 
v1.9. Odds ratios (OR) and 95% confidence intervals (CI) were computed using additive 
logistic regression. We adjusted for sex, age at recruitment, and 10 principal components 
(PCs). To determine the number of independent loci from the GWAS analysis, linkage 
disequilibrium (LD) clumping was performed using PLINK v1.9. SNPs with a p value <1x10-5, 
r2 >0.1, and a 500kb window from the index SNPs were assigned to the clump. Annotation of 
lead SNPs was conducted using the SNP2GENE tool of the Functional Mapping and 
Annotation of Genome Wide Association Studies (FUMA-GWAS).17 Pairwise LD patterns from 
SNPs identified as independent, located in the same gene or less than 500kb apart, were 
further analysed using the R package LDlinkR 18 19 which uses the 1000 Genomes Project 
data as the reference panel. HaploView was used to generate the LD plot.20 For the discovery 
analysis, genome wide significance was set at p=5x10-8. 
For replication analysis, the thirteen variants that reached genome wide significance in the 
discovery analysis were tested for association with gout in the replication cohort. Logistic 
regression was adjusted for sex, age, and 10 PCs. A Bonferroni corrected p value of <0.004 
(0.05/13) was used to determine significant associations in the replication analysis. The results 
from the discovery GWAS and the replication analysis were combined by meta-analysis using 
PLINK. The fixed-effects model was used to estimate pooled ORs and 95% CI, and Cochran’s 
Q test p values and I2 values were used to assess heterogeneity.  
Linear regression was used to examine the effect of GWAS hits on SU levels. This was 
performed using the full cohort, and adjusted for sex and age at recruitment. Beta coefficients 
and standard errors (SE), and adjusted Beta coefficients and SE were calculated. As previous 
GWAS 10 21 have used a cut-off of 7.0 mg/dl to define hyperuricaemia, a sensitivity analysis 
was conducted to evaluate if the association of GWAS hits and gout remained significant if 
controls had a SU ≥7.0 mg/dL. 
 
PRS: PRS was calculated using PRSice-2.22 The discovery GWAS summary statistics were 
used as the base dataset, while the replication cohort genotype-phenotype data were used as 
the target dataset. Clumping parameters in PRSice were set to an r2 >0.1 and a 500kb window 
from the index SNPs, which generated a final number of 266,754 SNPs available for PRS 
calculation. Odds ratios (OR) and p values from the GWAS summary statistics were used to 
calculate the best PRS model, which was generated from testing different p value thresholds. 
The best-fit model was defined by the largest Nagelkerke’s R2 value. Logistic regression was 
used to estimate the effect of the demographic variables for inclusion into the predictive 
models using SPSS Statistics 24. The area under the receiving operatic characteristic curve 
(AUROC) was used to evaluate the predictive ability of the PRS, demographic characteristics 
(age, sex and body mass index (BMI)), and combined models. 
 
Gout vs. normouricaemia GWAS: Two GWAS were conducted. Prior to conducting these 
analyses, both datasets underwent the same genotyping QC filters as described earlier. The 
association tests were performed with PLINK v1.9, using age, sex and the first 10 PCs as 
covariates.   
RESULTS  
Demographic characteristics: Following genotype QC filters, data for 7,049 gout cases and 
81,354 AH controls were included. The entire cohort comprised of 80.77% men, and their 
mean (SD) age, BMI, and SU were 57.87 (7.77) years, 29.63 (4.81) kg/m2, and 6.92 (0.88) 
mg/dL respectively. This cohort was divided into the discovery and replication datasets (Table 
1, Figure 1). The two datasets had comparable disease and demographic characteristics.  
Gout vs. AH:  
GWAS: An additive logistic regression was performed to test the association between gout 
and 710,030 variants. Thirty-four SNPs reached genome wide significance and after filtering 
for tight LD (r2<2.0), 13 SNPs were identified as independent associations (Figure 2). These 
lead SNPs were selected for the replication study, where they were tested for association with 
gout in the remaining 30% of the dataset. Successful replication was defined if the p value 
was < 0.004. Summary results for both the discovery and the replication analyses are shown 
in Table 2. The SNP with the greatest effect was rs2231142 in ABCG2 gene with OR=1.66 
(2.05x10-78) in the discovery stage, and OR=1.64 (1.17x10-32) in the replication stage. This 
was followed by a novel locus: rs1229984 in ADH1B gene (OR=1.51, p=5.00x10-12; OR=1.44, 
p=4.77x10-5). The remaining SNPs were located in or near GCKR, PPM1K-DT, SLC2A9, 
MEPE, LOC105377323, and SLC22A11. Pairwise LD parameters were evaluated for SNPs 









Table 1. Demographic, life-style and comorbidities for gout cases and asymptomatic hyperuricaemia controls of 
the UK Biobank 
  Discovery GWAS Replication stage 
 All  Gout cases Controls Gout cases  Controls 
  (88,403) (4,934) (56,948) 2,115 24,406 
Age at recruitment, years, mean (SD) 57.87 (7.77) 60.11 (6.88) 57.67 (7.82) 60.06 (6.81) 57.69 (7.80) 
Male sex, n (%) 71,401 (80.77) 4,529 (91.79) 45,506 (79.91) 1,950 (92.20) 19,416 (79.55) 
BMI, kg/m2, mean (SD) 29.63 (4.81) 30.79 (4.96) 29.53 (4.78) 30.62 (4.93) 29.53 (4.78) 
Waist circumference, cm, mean (SD) 99.56 (11.74) 103.76 (12.14) 99.23 (11.64) 103.49 (12.12) 99.16 (11.64) 
SU, mg/dL, mean (SD) 6.92 (0.88) 6.74 (1.78) 6.94 (0.76) 6.77 (1.74) 6.93 (0.75) 
Alcohol intake, n (%)*      
Never 4,397 (4.97) 221 (4.48) 2,822 (4.96) 85 (4.02) 1,269 (5.20) 
Special occasions 6,698 (7.58) 272 (5.51) 4,405 (7.74) 115 (5.44) 1,906 (7.81) 
<1/week 7,588 (8.58) 278 (5.63) 5,006 (8.79) 128 (6.05) 2,176 (8.92) 
1-2/week 21,908 (24.78) 1,093 (22.15) 14,190 (24.92) 496 (23.45) 6,129 (25.11) 
3-4/week 23,370 (26.44) 1,351 (27.38) 15,035 (26.40) 589 (27.85) 6,395 (26.20) 
Daily or almost daily 24,365 (27.56) 1,710 (34.66) 15,448 (27.13) 701 (33.14) 6,506 (26.66) 
Smoking status, n (%)* 
     
Non-smoker 41,778 (47.26) 1,998 (40.49) 27,243 (47.84) 862 (40.76) 11,675 (47.84) 
Ex-smoker 37,705 (42.65) 2,481 (50.28) 23,871 (41.92) 1,065 (50.35) 10,288 (42.15) 
Current smoker 8,590 (9.72) 434 (8.80) 5,613 (9.86) 183 (8.65) 2,360 (9.67) 
Comorbidities, n (%)      
Metabolic syndrome, n (%) 40,049 (45.30) 2,999 (60.78) 24,900 (43.72) 1,325 (62.65) 10,825 (44.35) 
Diabetes Mellitus 5,389 (6.10) 589 (11.94) 3,205 (5.63) 245 (11.58) 1,350 (5.53) 
Hypertension 35,776 (40.47) 2,824 (57.24) 22,206 (38.99) 1,241 (58.68) 9,505 (38.95) 
Hypercholesterolemia 15,831 (17.91) 1,368 (27.73) 9,737 (17.10) 585 (27.66) 4,141 (16.97) 
Ischaemic Heart Disease 6,817 (7.71) 666 (13.50) 4,051 (7.11) 290 (13.71) 1,810 (7.42) 
Cardiac failure 133 (0.15) 28 (0.57) 62 (0.11) 18 (0.85) 25 (0.10) 
Chronic Kidney Disease stages*      
G1 (>90 ml/min 39,800 (45.02) 1,962 (39.76) 25,849(45.39) 855 (40.43) 11,134 (45.62) 
G2 (60-90 ml/min) 43,774 (49.52) 2,434 (49.33) 28,260 (49.62) 1,026 (48.51) 12,054 (49.39) 
G3a (45-59 ml/min) 3,722 (4.21) 343 (6.95) 2,258 (3.97) 159 (7.52) 962 (3.94) 
G3b (30-44 ml/min) 792 (0.89) 138 (2.80) 419 (0.74) 40 (1.89) 195 (0.80) 
G4 (15-29 ml/min) 213 (0.24) 41 (0.83) 106 (0.19) 22 (1.04) 44 (0.18) 
G5 (<15 ml/min) 51 (0.06) 13 (0.26) 19 (0.03) 12 (0.57) 7 (0.03) 
      
*The following data were missing: alcohol intake for 0.09%, smoking satus for 0.73%, and CKD information for 
0.06%. 
Diabetes, hypertension, hypercholesterolemia,ischaemic heart disease and cardiac failure were defined as 
present if they were self-reported as diagnosed by a doctor. Chronic Kidney Disease stages were defined as per 
the National Institute of Heath and Care Excellence (NICE) guidelines CG182.23 Metabolic syndrome was 
calculated as recommended by the International Diabetes Federation in 2006.24  
Table 2. Summary of GWAS and replication analysis of 13 lead SNPs in gout cases and AH controls (SU >= 6 mg/dL). 
 
1Fixed-effects meta-analysis of the discovery GWAS and the replication analysis. 
2Adjusted for age, sex, and 10 first PCs 
A1, allele 1/effect allele; Bp, base pair position; Chr, chromosome; Freq, frequency; OR, Odds Ratios; SNP, single nucleotide polymorphism  
                        
      Discovery GWAS Replication stage Meta-Analysis
1 




rs1260326 2 27730940 GCKR T 0.41 1.13 (1.08-1.17) 3.54x10-08 1.15 (1.08-1.23) 2.54x10-05 1.14 (1.10-1.18) 5.10x10-12 0.61 0 
rs2231142 4 89052323 ABCG2 T 0.14 1.66 (1.58-1.76) 2.05x10-78 1.64 (1.51-1.78) 1.17x10-32 1.65 (1.58-1.73) 3.33x10-109 0.75 0 
rs13120400 4 89033527 ABCG2 C 0.28 0.82 (0.78-0.86) 1.56x10-16 0.84 (0.78-0.91) 3.43x10-06 0.83 (0.79-0.86) 3.66x10-21 0.50 0 
rs7672194 4 89126647 ABCG2 T 0.48 1.16 (1.11-1.21) 3.21x10-12 1.15 (1.08-1.23) 1.13x10-05 1.16 (1.12-1.20) 1.58x10-16 0.88 0 
rs4693211 4 89249061 PPM1K-DT C 0.07 1.41 (1.31-1.52) 6.97x10-20 1.26 (1.12-1.42) 1.21x10-04 1.37 (1.28-1.45) 1.55x10-22 0.11 61.62 
rs28793136 4 89216768 PPM1K-DT C 0.08 1.35 (1.26-1.45) 8.19x10-17 1.26 (1.12-1.40) 6.29x10-05 1.32 (1.25-1.40) 4.79x10-20 0.27 19.60 
rs1545207 4 89239492 PPM1K-DT A 0.28 1.14 (1.09-1.20) 6.82x10-09 1.12 (1.05-1.20) 1.07x10-03 1.14 (1.09-1.18) 3.38x10-11 0.66 0 
rs16890979 4 9922167 SLC2A9 T 0.17 0.79 (0.74-0.83) 3.19x10-16 0.73 (0.67-0.80) 1.05x10-11 0.77 (0.74-0.81) 5.45x10-26 0.19 42.09 
rs16891234 4 9946163 SLC2A9 C 0.24 1.16 (1.11-1.22) 6.06x10-10 1.13 (1.05-1.22) 8.86x10-04 1.15 (1.11-1.20) 2.72x10-12 0.57 0 
rs1229984 4 100239319 ADH1B T 0.03 1.51 (1.34-1.69) 5.00x10-12 1.44 (1.21-1.72) 4.77x10-05 1.49 (1.35-1.64) 1.15x10-15 0.68 0 
rs114791459 4 88591554 LOC105377323 A 0.02 1.42 (1.26-1.60) 7.99x10-09 1.47 (1.22-1.77) 5.47x10-05 1.43 (1.30-1.59) 2.01x10-12 0.76 0 
rs114580333 4 88790118 MEPE A 0.02 1.44 (1.26-1.63) 3.01x10-08 1.39 (1.15-1.69) 9.18x10-04 1.42 (1.28-1.59) 1.10x10-10 0.79 0 
rs2078267 11 64334114 SLC22A11 C 0.47 1.16 (1.11-1.21) 1.72x10-12 1.14 (1.07-1.22) 6.27x10-05 1.15 (1.11-1.20) 6.65x10-16 0.62 0 
Genetic variants and SU: All lead SNPs associated with SU, with rs2231142 (ABCG2) and 
rs16890979 (SLC2A9) showing the greatest effects: adjusted β=0.107 and p=1.21x10-80, and 
adjusted β=-0.055 and p=1.67x10-43 respectively (Table S1). On sensitivity analysis examining 
the association between 13 lead SNPs and gout, excluding AH controls with SU <7.0 mg/dL, 
the ORs diminished in magnitude but remained significant (Table S2).  
 
PRS model: A PRS for all cases and controls was constructed with PRSice using the 
replication cohort as the test dataset. The best-fit p value threshold that gave the highest 
Nagelkerke’s R2 (0.016) was 4.0x10-6, and included 17 SNPs (Table S4). The mean (±SD) 
PRS for cases was 0.018 (±0.017), and 0.013 (±0.016) for controls (p <0.0001). The predictive 
ability of this PRS model was evaluated using the AUROC curve, and compared to the 
demographics model (age, sex and BMI) and combined model (age, sex, BMI and PRS). The 
AUC for each model was 58.5%, 66.7%, and 69.2% respectively (Figure 3). 
 
Gout vs. normouricaemia: We conducted two GWAS of gout vs normouricaemia using SU cut-
off values <6.0 mg/dL and <7.0 mg/dL respectively. The first GWAS identified 52 lead SNPs, 
while the second identified 46 lead SNPs (Table S3). Three novel SNPs (rs760077, 
rs3800307, and rs11227299 in MTX1, PRSS16, and AP5B1 genes respectively) associated 
with gout compared to SU <6mg/dL with GWAS significance. Two (rs760077 and rs3800307) 
remained GWAS significant when a higher SU threshold of <7 mg/dL was used to define 
normouricaemia.  We then plotted the OR of each lead SNP in the gout vs AH-control GWAS 
and the gout vs SU <6mg/dL GWAS (Figure 4A). To be consistent with our sensitivity analysis, 
we plotted the OR of the thirteen lead SNPs upon excluding AH controls with SU 6-7mg/dL, 
with the gout vs SU <7mg/dL GWAS (Figure 4B). Same loci were responsible for transition 
from AH and normouricaemia to gout.  
 
 
DISCUSSION This is the largest GWAS to date and the first in Caucasians to examine the 
SNPs associated with transition from AH to gout. Using UK Biobank data, it identified 13 
independent SNPs from eight loci that reached genome wide significance for association with 
gout vs. AH, and replicated. These loci include urate transporters, metabolic pathway genes 
(e.g. GCKR, ADH1B), and MEPE gene that regulates renal phosphate handling and skeletal 
mineralization.25 The latter may promote progression to gout via pro-mineralising osteopontin 
like function or via low phosphate levels that associates with incident hyperuricaemia.26 The 
identified loci in PPM1K-DT and LOC105377323 were in non-coding regions and their 
molecular mechanism is unclear.  
Of the eight loci, ABCG2, SLC2A9, SLAC22A11, PPM1K-DT, GCKR, and MEPE have 
previously been associated with gout or SU levels in different populations but never in the 
transition from AH to gout in a GWAS.5 21 27 28 This is the first such report. In a previous study, 
Tin et al generated a genetic risk score using variants associated with SU and examined their 
ability to predict gout cases in 334,800 UK Biobank participants not specifically selected for 
high SU levels. Ours is the first study to attempt to generate a PRS for predicting gout status 
in an AH population i.e. those with SU ≥6.0 mg/dL, and reports an AUC of 58.5% for genetic 
factors alone, that increased to just under 70% when demographic factors were added. This 
is lower than the AUC of 67.2% from genetic factors alone in the study by Tin et al and is likely 
to be due to lower genetic variance due to selection of a high SU control group.27 A smaller 
study using candidate gene hypothesis reported nominal association for ABCG2 
polymorphism and gout vs. hyperuricaemia.29 The only previous gout vs. hyperuricaemia 
GWAS was conducted in a Japanese population and reported rs7927466 in CNTN5, 
rs9952962 in MIR302F, and a suggestive locus rs12980365 in ZNF724 that do not affect SU.10 
Although rs7927466 is not included in the UK Biobank genotype platform, it is covered by its 
proxy SNP rs7942264 (r2=1) that did not show an association with gout; neither did 
rs12980365. MIR302F was not included in UK Biobank and further research on this gene is 
needed. 
ADH1B was identified as a risk variant for gout vs. AH. It has never previously been associated 
with gout in a GWAS – even when compared to general population. ADH1B, mediates the 
oxidation of ethanol into acetaldehyde.30 The SNP rs1229984 in ADH1B causes a change of 
an arginine to histidine, increases ethanol clearance in liver, facilitates its’ conversion to highly 
reactive acetaldehyde31, increases the NADH/NAD ratio that results in high lactic acid levels 
and increased urate reabsorption via URAT1.32 The risk allele of rs1229984 also promotes a 
“flush response” to alcohol and reduces the amount of alcohol consumed33. Thus, the 
association between this polymorphism and gout may be due to increased production and 
reabsorption of urate from per unit alcohol consumed. This is consistent with the observation 
by Yokoyama et al in which rs1229984 associated with SU≥7 mg/dL (OR (95%CI) 2.04 (1.58–
2.65)), while the daily alcohol intake was comparable across variants.34 In agreement with our 
study, Sakiyama et al (n=1,048 gout cases and 1,334 male controls) evaluated the effect of 
rs1229984 in ADH1B gene on gout. They, reported an increased risk for gout with OR of 1.69 
and 1.80 for His/Arg and His/His genotypes respectively, that remained significant after 
correcting for alcohol consumption.35 However, in their study patients with gout and rare 
variants of the SNP had greater alcohol consumption, suggesting an additional role for the 
latter.  
Urate transporters ABCG2, SLC2A9 and SLC22A11 play essential roles in pathogenesis of 
hyperuricaemia.36 37 SLC2A9 has the strongest effect on SU, accounting for 2-3% of variance, 
followed by ABCG2 that explains 1% of SU variation.37 Although both loci have also been 
associated to gout, GWAS of gout cases vs controls, have shown a greater effect of ABCG2 
than SLC2A9.7 In this study, rs2231142 in ABCG2 had larger effect size on gout status 
compared to AH-control than that of rs16890979 in SLC2A9 (which is in tight LD with the 
GWAS hit rs12498742) and also twice as much effect on SU than the latter. This supports the 
hypothesis that ABCG2, plays a causal role in transition from hyperuricaemia to gout via its 
effect on SU. However, additional mechanisms such as defects in ABCG2 causing deficient 
autophagy may also operate.29 38   
 
Our GWAS comparing gout cases with normouricaemic controls did not identify any 
inflammatory genes. A large number of lead SNPs were identified at genome-wide significance 
level. Most have been associated with gout or SU previously.5 7 27 28 39 However, we identified 
three novel SNPs associated with gout compared to SU <6.0 mg/dL. Of these, rs11227299 
(AP5B1) is associated with reduced eGFR and may cause gout by resulting hyperuricemia.40 
The variants in MTX1 and PRSS16 genes associated with gout compared to SU <6.0 mg/dL, 
also associate negatively with Parkinson’s Disease and Schizophrenia.41 42 This is consistent 
with the negative associations between Parkinson’s Disease and gout, and Schizophrenia and 
elevated SU.43 44  
This is the first GWAS to examine transition from AH to gout in Caucasians. Other strengths 
include a large sample size, and assessment of transition from AH or normouricaemia to gout 
in the same source population. However, there are several caveats to this study. Firstly, gout 
definition was not based on ACR/EULAR classification criteria, but was ascertained via self-
report of physician diagnosis, hospital diagnoses and ULT prescriptions. However, the UK 
Biobank data collection predates the classification criteria. In addition, the classification of AH 
controls was based on a single SU measurement which could have been affected by diet 
during the previous days. Additionally, the use of non-imputed data limited the discovery power 
of the GWAS and PRS. 
In conclusion, this study identified 13 GWAS significant risk loci, 12 of which have never 
previously been associated with the transition from AH to gout at GWAS level. The 
preponderance of urate transporters and metabolic genes that affect SU levels support the 
central role of hyperuricaemia in the pathogenesis of gout. Larger GWAS are required to 
identify if variants in inflammatory pathways also contribute to this transition. 
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Figure 1 Study design. Workflow for the discovery and replication analyses. QC, quality control; SD, standard 
deviation; HWE, Hardy-Weinberg equilibrium; SNPs, single nucleotide polymorphisms; PCs, principal components. 
Figure 2. Manhattan plot of the discovery GWAS of gout vs. AH (SU ≥6.0 mg/dL) controls. The y-axis shows –
log10 P values ordered by chromosomal position on the x-axis. The horizontal dashed-line represents genome 
wide significance threshold (5.0x10-8). 
Figure 3. Area under the receiver operating characteristics (AUROC) curve for the PRS model, demographics 
model, and combined (demographics + PRS) model. 
Figure 4. Scatter plot. A) Comparison of the ORs of lead SNPs for both GWAS: gout vs asymptomatic 
hyperuricaemia (SU ≥6.0 mg/dL) and gout vs SU <6.0 mg/dL. Black dots represent ORs of the common risk loci of 
both GWAS, while grey circles represent ORs of additional lead SNPs of the gout vs SU<6.0 mg/dL that were not 
significant at GWAS level in the gout vs asymptomatic hyperuricaemia GWAS. B) Comparison of the ORs of the 
thirteen lead SNPs for gout vs asymptomatic hyperuricaemia (defined as SU ≥7.0 mg/dL), compared to the ORs in 
the GWAS for gout vs SU <7.0 mg/dL. Where several SNPs were present in the same gene, only that with the 
smallest p value was plotted in this graph. See Supplementary material for names of genes not annotated in the 
figure. 
 
